Is anti-IgE therapy effective in preventing magnesium and selenium loss in bones of mice with chronic allergic asthma?
Nural, Yahya | Erdal, Nurten | Uzun, Coşar
Objective: Chronic allergic asthma (CA) is a respiratory disease that affects millions of people worldwide. While there is evidence linking airway hyperresponsiveness and asthma to factors related to bone metabolism, the impact of asthma on bone health is not well understood. Therefore, to explore whether: (i) CA causes meaningful changes in bone magnesium (Mg) and selenium (Se) levels, and if any, (ii) anti-IgE (anti-immunoglobulin E) treatment has a protective effect against these changes. Methods: In present study used tibia bones from a previous study on CA in mice. A murine model was used to generate CA. Thirty-two BALB/c male mice were randomly divided into four equal sized groups (eight mice/group): control group (intact), CA (treated with saline (0.9% NaCl), CA+L-AIgE (100 μg of a...
Does anti-IgE therapy prevent chronic allergic asthma-related bone deterioration in asthmatic mice?
Nural, Yahya
Current evidence on the association between allergic diseases and bone metabolism indicates asthma may be a potential risk factor for bone health. Using anti-IgE has been proven effective in allergic asthma treatment with a good safety profile; however, its effects on bone health are unknown. Thus, we aimed to investigate whether: (i) chronic allergic asthma (CAA) causes any meaningful changes in bone, and if any, (ii) anti-IgE therapy prevents any CAA-induced adverse alteration. A murine model was used to study CAA. Thirty-two BALB/c male-mice were assigned into four groups (eight-mice/group): Control, CAA (treated with saline), CAA + 100 mu g of anti-IgE (CAA + 100AIgE), and CAA + 200 mu g of anti-IgE (CAA + 200AIgE) groups. After immunization, saline or anti-IgE was performed intraperit...
Anti-Ige Therapy Prevents Chronic Allergic Asthma-Related Deterioration of Bone Quality in Asthmatic Mice: A Biomechanical & ICP-MS Study
Nural, Yahya
Aim: Recent studies suggest an association between allergic diseases, including asthma, and bone loss. However, it is not yet clearly known whether chronic allergic asthma (CAA) cause bone deterioration and/or anti-IgE therapy used in asthma treatment prevent bone quality. Thus, the aim of the study was to investigate whether: i) CAA cause meaningful changes in bone quality and ii) anti-IgE therapy have protective effects on asthma-related bone loss and bone deterioration if any. Methods: We used a chronic inhalational exposure model of asthma in ovalbumin-sensitized BALB/c male mice (8-10 weeks-old) to generate CAA. Thirty-two mice were assigned randomly into four groups (eight mice per group): control (intact group), CAA (treated with saline), CAA+100 µg of anti IgE, and C...
Kombı̇ne Flutı̇kazon/antı̇-Ige tedavı̇sı̇ astımlı farelerde kemı̇k bozulmasını önler mı̇?
Nural, Yahya | Uzun, Coşar | Erdal, Nurten
Amaç: Çalışmanın amacı, i) Kronik alerjik astım'ın (KAA) kemik kalitesinde anlamlı değişikliklere neden olup olmadığını, eğer varsa, ii) flutikazon ve iii) flutikazon ve anti-IgE içeren kombine tedavinin astım-nedenli kemik kaybı ve kemik bozulması üzerinde koruyucu etkileri olup olmadığını araştırmaktır. Yöntem: Çalışmada, KAA oluşturmak amacıyla ovalbumin ile duyarlılaştırılmış BALB/c erkek farelerde (8-10 haftalık) astıma özgü kronik inhalasyonel maruziyet modeli kullanıldı. Otuz-iki adet fare her gruba eşit-sayıda hayvan gelecek şekilde 4 gruba ayrıldı: control (tedavi verilmedi), KAA (salin verildi), KAA+2000µg flutikazon ve KAA+kombine tedavi (2000µg flutikazon+200µg anti-IgE). İmmünizasyon sonrası, aerosolize flutikazon veya salin haftada üç kez inhalasyon yoluy...